溶瘤病毒疗法在肿瘤微环境与 CAR 治疗交界处的作用:机制、临床转化与未来方向
Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.
溶瘤病毒疗法已从一种肿瘤选择性溶细胞策略演变为一种可编程的免疫治疗平台,能够重塑肿瘤微环境(TME)。
67.6分
★★★☆☆
FRONTIER PAPERS
Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.
溶瘤病毒疗法已从一种肿瘤选择性溶细胞策略演变为一种可编程的免疫治疗平台,能够重塑肿瘤微环境(TME)。
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
TNBC仅占新发乳腺癌诊断的约15%-20%;
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。